How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
ADC Drug Market
- By Payload Type: Cytotoxic Agents, Immunotoxins, Radioisotopes, Enzymes
- By Linker Type: Cleavable Linkers, Non-Cleavable Linkers
- By Target Antigen: HER2, CD33, CD30, CD22, Trop-2
- By Indication: Hematological Malignancies, Breast Cancer, Lung Cancer, Gastrointestinal Cancers, Other Solid Tumors
- By Stage of Development: Preclinical, Clinical Trials, Commercialized
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cytotoxic Agents leads By Payload Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the ADC Drug Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Payload Type 4
Linker Type 2
Target Antigen 5
Indication 5
Stage of Development 3
Companies profiled
Seagen Inc.
Roche Holding AG
Pfizer Inc.
Astellas Pharma Inc.
ImmunoGen Inc.
Daiichi Sankyo Company
Limited
Amgen Inc.
Mersana Therapeutics Inc.
Seattle Genetics (a Seagen company)
Genmab A/S
MabVax Therapeutics Holdings Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Seagen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Holding AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Astellas Pharma Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ImmunoGen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Daiichi Sankyo Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Amgen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Mersana Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Seattle Genetics (a Seagen company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Genmab A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →MabVax Therapeutics Holdings Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Synaffix B.V.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →CytomX Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sorrento Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Zymeworks Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,748M by 2033 · 4.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cytotoxic Agents54.3
- Immunotoxins18.7
- Radioisotopes8.1
- Enzymes18.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,785M → $2,881M · 6.2%
Europe$1,244M → $1,764M · 4.5%
Asia Pacific$1,136M → $1,769M · 5.7%
Latin America$703.2M → $1,100M · 5.8%
Middle East and Africa$541.0M → $739.8M · 4.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.542026
4.552027
4.562028
4.572029
4.602030
4.612031
4.622032
4.632033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Seagen Inc.11.0
- Roche Holding AG15.7
- Pfizer Inc.10.3
- Astellas Pharma Inc.14.5
- ImmunoGen Inc.9.1
- Daiichi Sankyo Company11.5
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Payload Type30.3%
Linker Type25.8%
Target Antigen9.0%
Indication20.6%
Stage of Development14.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.9
- Europe21.4
- Asia Pacific21.4
- Latin America13.3
- Middle East and Africa9.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Seagen Inc. | 95 | 86 | 76 | 85 | 77 | 92 | 85 |
| Roche Holding AG | 73 | 87 | 74 | 92 | 78 | 69 | 79 |
| Pfizer Inc. | 64 | 77 | 69 | 86 | 74 | 87 | 76 |
| Astellas Pharma Inc. | 57 | 69 | 78 | 70 | 63 | 58 | 66 |
| ImmunoGen Inc. | 68 | 64 | 55 | 68 | 62 | 65 | 64 |
| Daiichi Sankyo Company | 57 | 49 | 67 | 71 | 58 | 50 | 59 |
| Limited | 54 | 46 | 61 | 51 | 66 | 41 | 53 |
| Amgen Inc. | 43 | 59 | 54 | 46 | 49 | 39 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Seagen Inc.
- Roche Holding AG
- Pfizer Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Seagen Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Roche Holding AG | ✓ | ✓ | − | ◐ | ✓ | ◐ |
| Pfizer Inc. | ◐ | ✓ | − | ✓ | ◐ | ✓ |
| Astellas Pharma Inc. | − | − | ✓ | ◐ | − | ◐ |
| ImmunoGen Inc. | ✓ | ✓ | − | − | ◐ | ◐ |
| Daiichi Sankyo Company | ◐ | − | ✓ | ◐ | ◐ | − |
| Limited | − | − | ✓ | ◐ | ◐ | − |
| Amgen Inc. | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Seagen Inc.85
2Roche Holding AG79
3Pfizer Inc.76
4Astellas Pharma Inc.66
5ImmunoGen Inc.64
6Daiichi Sankyo Company59
7Limited53
8Amgen Inc.48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Seagen Inc.Roche Holding AG
Challenger1
Strong scale, closing on the leaders.
Pfizer Inc.
Contender3
Focused players with pockets of strength.
Astellas Pharma Inc.ImmunoGen Inc.Daiichi Sankyo Company
Niche2
Specialists in a single segment or region.
LimitedAmgen Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Payload Type in North America, then scale across ADC Drug Market — a $611M beachhead inside a $9.24B market.
Beachhead (SOM)$611Mobtainable near-term
Serviceable (SAM)$3.44Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Cytotoxic Agents
Best fit — highest urgency & budget in Payload Type.
Economic buyer80 fit
Immunotoxins
Strong fit — clear ROI and a fast path to value.
End user68 fit
Radioisotopes
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Payload Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Linker Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Target Antigen
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Payload Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win ADC Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified25%
Evaluation12%
Closed-won6%
$19.8KCAC
$75KLTV
3.8:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
ADC Drug Market is a resilient opportunity — $3.60B by 2033, compounding at 3.9%.
TAM · 2025$2.65Btoday
TAM · 2033$3.60Bforecast
CAGR3.9%2027–2033
Cumulative$27.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.60BTotal addressable market
SAM$1.25BServiceable available market
SOM$226MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.9% CAGR
Demand compounds through 2033, outpacing GDP across Payload Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Payload Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.60BLarge & growingTAM by 2033 at 3.9% CAGR
$1.25BServiceable nowreachable with today’s model
$226MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.81BBear2.5% CAGR
$3.60BBase3.9% CAGR
$4.61BBull5.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Linker Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
ADC Drug Market — a $8.30B market by 2033. Plan: grow share from 7.1% to 12.6%.
Market size · 2033$8.30Btotal addressable
Market CAGR5.5%2027–2033
Target share12.6%from 7.1% today
Revenue ambition$1.05Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.1% | 12.6% | At risk |
| Revenue | $615M | $1.05B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 34.0% | 45.1% | Behind |
| Customer retention | 84.7% | 92.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Payload Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Linker Type capability
A defensible second engine — invest in Linker Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Payload Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Linker Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $135M capacity & capability investment
- Greenlight bolt-on M&A in Linker Type
- Authorise North America expansion plan
- Fund R&D program for Payload Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the ADC Drug Market conversation — a $3.23B market you can size, segment and defend in minutes.
Market size · 2033$3.23Btotal opportunity
Growth8.7%CAGR to 2033
Addressable buyers961+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Payload Type
Goal Grow share in Payload Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 4 mopayback period
$96K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Seagen Inc.Roche Holding AGPfizer Inc.Astellas Pharma Inc.ImmunoGen Inc.Daiichi Sankyo CompanyLimitedAmgen Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your ADC Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
ADC Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Web-based Recruitment Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportAdaptive Switches Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportAdaptive Strollers for Special Needs Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportAdaptive Servo-Ventilators (ASV) Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportAdaptive Lenses Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportWaiver Software Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportAdaptable Alternating Pressure Systems Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportAdapalene Products Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportAdapalene Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportAdapalene Gel Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportAdapalene Benzoyl Peroxide Gel Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportAdapalene API Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.